{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Shingles vaccination has promising local causal evidence for preventing or delaying dementia diagnoses; product-wide efficacy, causal magnitude and the mediator remain unsettled.",
  "implications": "The preregistered primary-subclaim rule returns Δ from SC2: the strongest evidence is a positive local age-eligibility natural experiment for live-zoster vaccination and recorded dementia, with international eligibility corroboration. Multiple related discontinuity analyses do not automatically supply independently failing causal modalities. Receipt-effect assumptions, a quantitative2026 critique, diagnosis ascertainment, product transfer and exploratory sex boundaries prevent a higher grade. Weakest-link returns Β; primary and scope-matched return Δ. This is stronger than an ordinary association but remains a bounded causal-inference judgment rather than completed randomized dementia-prevention proof.",
  "limitations": "53 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}